The Universities of York and Newcastle have joined forces with two leading cancer charities to create a new biobank which will provide vital resources for researchers working to prevent, diagnose and treat cancer in children and young people.
The samples will form a crucially important resource as many children and young people's cancers
VIVO Biobank is supported by the charities Cancer Research UK and Blood Cancer UK and will provide cancer researchers with a centralised collection of cell and tissue samples from children and young people affected by cancer across the country.
The samples will form a crucially important resource as many children and young people's cancers are extremely rare. This has made it difficult for researchers to access sufficient samples from patients in order to study them.
VIVO Biobank is a merger of two existing biobanks - one dedicated to the study of leukaemia at York and another for the study of solid tumours at Newcastle. The merging of the Banks also allows additional genetic and clinical data to be made available, aiding research into these cancers.
More data
There are around four thousand new cancer cases in children and young people in the UK every year.
Co-Deputy Director of VIVO Biobank, Professor Alexandra Smith from the Epidemiology and Cancer Statistics Group in the Department of Health Sciences at the University of York, said: "Bringing our biobanks together is going to enable more children and young people to donate samples and along with the additional clinical data provide an invaluable resource for scientists.
"This will make more research possible on prevention, diagnostics and treatments for children and young people with cancer than ever before."
Leading the way
Director of VIVO Biobank, Professor Deb Tweddle from the Translational & Clinical Research Institute and the Centre for Cancer at Newcastle University said: "This is a huge opportunity for the UK to lead the way in Children's and Young people's cancer research by providing a single point of access to researchers for precious samples, particularly for researchers who may want to work on many different types of cancer.
"Around 80% of childhood and young people's cancer is cured by current treatments and we hope VIVO biobank will promote research for those types not currently curable and lead to the development of kinder treatments for others."
